VAM (liposomal mitoxantrone) for secondary AML and myeloid sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2, interventional trial of a liposomal mitoxantrone formulation designed to enhance tissue penetration and reduce circulating free drug, with the goal of lowering cardiotoxicity compared with conventional mitoxantrone. The study enrolls adults with newly diagnosed, previously untreated non-APL AML who have secondary or therapy-related disease, extramedullary involvement, or myeloid sarcoma, and who meet cardiac and organ-function criteria. Participants receive VAM as the investigational chemotherapy regimen and are followed for treatment response, adverse events, and cardiac safety. The trial is conducted at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, with structured clinical and laboratory monitoring throughout therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The patient fully understands this study, voluntarily participates, and signs the informed consent form (ICF)
2. Age 18-65 years
3. Clinically diagnosed, previously untreated acute myeloid leukemia (non-APL), meeting any one of the following criteria: a. Secondary acute myeloid leukemia; b. Therapy-related acute myeloid leukemia; c. AML with extramedullary/myeloid sarcoma; d. Age ≥60 years, assessed as fit-AML;
4. Normal cardiac function, with left ventricular ejection fraction (LVEF) ≥50%
5. Liver and kidney function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the upper limit of normal (ULN) (≤5 times ULN for patients with liver involvement); total bilirubin ≤1.5 times ULN; serum creatinine ≤1.5 times ULN
6. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-2

Exclusion Criteria:

1. Assessed as unfit- or frail-AML;
2. Patients with a history or concurrent diagnosis of other malignancies requiring treatment
3. Uncontrolled systemic diseases (e.g., advanced active infections, uncontrolled hypertension, etc.)
4. Known history of immediate or delayed hypersensitivity reactions to the same class of study drugs or excipients
5. Pregnant or breastfeeding women, or patients who refuse to use effective contraception during the study period
6. Patients with a history of severe neurological or psychiatric disorders
7. Other severe medical conditions, such as myocardial infarction, severe or unstable angina, severe arrhythmias
8. Cerebrovascular events (including transient ischemic attacks), etc.
9. Known infection with human immunodeficiency virus (HIV); active hepatitis B or C infection; inactive hepatitis carriers or subjects with low viral titers after receiving non-prohibited antiviral therapy are not excluded
10. Subjects who have received strong or moderate CYP3A inducers/inhibitors or strong P-gp inhibitors or related foods within 7 days before starting the study treatment
11. Patients unable to take oral medications or with malabsorption syndrome
12. Patients deemed by the investigator to be unsuitable for participation in the study

Where it's running

• Ruijin Hospital, Shanghai Jiaotong University School of Medicine
  Shanghai, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intensive conditioning for myeloid cancers with extramedullary involvement

  This study is testing a new treatment plan using specific medications before a stem cell transplant to see if it helps people with myeloid cancers that have spread beyond the bone marrow feel better and have better outcomes.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06111612

• Investigating Ziftomenib with Other Treatments for Acute Myeloid Leukemia

  This study is testing if a new drug called ziftomenib, when combined with other treatments, can help people with acute myeloid leukemia who have certain genetic mutations feel better and stay safe during treatment.

  Recruiting at 44 sites Phase 1 Kura Oncology, Inc. · Phoenix, Arizona and 43 other locations · NCT05735184

• Using dexrazoxane to protect the heart during chemotherapy for blood cancers

  This study is testing if a drug called dexrazoxane can help protect the hearts of people with blood cancers from damage caused by chemotherapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03589729

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Characterization of CD180 Protein Expression in Myeloid Blood C cancers

  This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895901

• Personalized AML: Find biomarkers to predict response to venetoclax

  This study tests whether single-cell analyses can help group AML patients by biology and find biomarkers that predict who will respond to venetoclax.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07874100

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.